Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lobe Sciences Provides Update on L-130 Clinical Program
Details : The company’s lead clinical program, L-130 (psilocin Mucate), a proprietary stabilized conjugate drug candidate, 5-HT2A receptor agonist. It is being evaluating under Phase I clinical trial studies for the treatment of chronic cluster headaches.
Product Name : L-130
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2023
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
Details : L-130 (psilocin analogue), a proprietary stabilized psilocin analogue, which is invetigated for the treatment of chronic cluster headaches (CCH), the most predominant headache disorder within the group of trigeminal autonomic cephalgias (TACs).
Product Name : L-130
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : DHA
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Pentec Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : Pentec will receive the exclusive rights to distribute Altemia (docosahexaenoic acid ethyl ester), a proprietary oral formulation of emulsified docohexanoic acid, clinically evaluated to restore DHA levels and help reduce inflammation associated with SCD...
Product Name : Altemia
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 17, 2023
Lead Product(s) : DHA
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Pentec Health
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
